Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

NICE recommends GSK's Strimvelis for ADA-SCID

January 5, 2018 10:07 PM UTC

The U.K.'s NICE issued a final appraisal determination recommending Strimvelis (2696273, GSK2696273) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat adenosine deaminase (ADA) deficiency-severe c...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Glaxosmithkline plc

BCIQ Target Profiles

Adenosine deaminase (ADA)